Benjamin Gmeiner

Benjamin Gmeiner

Auto-generated profile, based on publicly available information

Benjamin Gmeiner

Novartis Pharma GmbH, Nürnberg, Bayern, Germany

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2023 in Nature Methods
Verified
Journal Article
Closed access
PDF file
HTHe Tian
He Tian
HDHunter C. Davis
Hunter C. Davis
JWJ. David Wong-Campos
J. David Wong-Campos
PPPojeong Park
Pojeong Park
LFLinlin Z. Fan
Linlin Z. Fan
ACAdam E. Cohen
Adam E. Cohen

7 May 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
Miao-Ping ChienMiao-Ping Chien
Miao-Ping Chien
DBDaan Brinks
Daan Brinks
GTGuilherme Testa-Silva
Guilherme Testa-Silva
HTHe Tian
He Tian
FBF Phil Brooks
F Phil Brooks
ACAdam E Cohen
Adam E Cohen
Photoactivated genetically encoded voltage indicators (GEVIs) have the potential to enable optically sectioned voltage imaging at the intersection of a photoactivation beam and an imaging beam. We developed a pooled high-throughput screen to identify archaerhodopsin mutants with enhanced photoactivation. After screening ~10 5 cells, we identified a novel GEVI, NovArch, whose one-photon near-infrared fluorescence is reversibly enhanced by weak one-photon blue or two-photon near-infrared excitation. Because the photoactivation leads to fluorescent signals catalytically rather than stoichiometrically, high fluorescence signals, optical sectioning, and high time resolution are achieved simultaneously at modest blue or two-photon laser power. We demonstrate applications of the combined molecular and optical tools to optical mapping of membrane voltage in distal dendrites in acute mouse brain slices and in spontaneously active neurons in vivo.

1 February 2013 in Computers & Mathematics with Applications
Verified
Journal Article
Closed access
BGB. Gmeiner
B. Gmeiner
TGT. Gradl
T. Gradl
FGF. Gaspar
F. Gaspar
URU. Rüde
U. Rüde

3 September 2020 in Physical Review Letters
Verified
Journal Article
Open access
PDF file
JZJohannes Zirkelbach
Johannes Zirkelbach
BGBenjamin Gmeiner
Benjamin Gmeiner
JRJan Renger
Jan Renger
PTPierre Türschmann
Pierre Türschmann
TUTobias Utikal
Tobias Utikal
VSVahid Sandoghdar
Vahid Sandoghdar
Extinction of light by material particles stems from losses incurred by absorption or scattering. The extinction cross section is usually treated as an additive quantity, leading to the exponential laws that govern the macroscopic attenuation of light. In this Letter, we demonstrate that the extinction cross section of a large gold nanoparticle can be substantially reduced—i.e., the particle becomes more transparent—if a single molecule is placed in its near field. This partial cloaking effect results from a coherent plasmonic interaction between the molecule and the nanoparticle, whereby each of them acts as a nanoantenna to modify the radiative properties of the other.

18 February 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FZFocke Ziemssen
Focke Ziemssen
HAHansjürgen Agostini
Hansjürgen Agostini
NFNicolas Feltgen
Nicolas Feltgen
RFRobert P. Finger
Robert P. Finger
CHChristos Haritoglou
Christos Haritoglou
BGBenjamin Gmeiner
Benjamin Gmeiner
Neovascular age-related macular degeneration (nAMD) is a progressive retinal disease that often leads to severe and permanent vision loss. Early initiation of anti-vascular endothelial growth factor (anti-VEGF) therapy has been shown to preserve vision in nAMD patients. Concurrently, treatment outcomes in real-world are inferior to those reported in clinical trials. The most likely reasons observed are fewer treatment-intensity in routine clinical practice than in clinical trials. The other possibility could be the delay in starting treatment and the re-treatment interval. Although a negative impact of aforementioned parameters seems obvious, quantitative impact measures remain elusive in a real-world setting due to a lack of an ‘optimal treatment’ control group. To overcome this shortcoming, we developed, validated, and applied a model to assess and quantify the impact of anti-VEGF administration variables on visual acuity development in a prospective nAMD patient cohort. The model was further applied to probe the impact of the COVID-19 pandemic on visual progressions in nAMD patients. The presented model paves the way to systematically explore and evaluate realistic interventions in the current treatment paradigm, that can be adopted in routine clinical care.

6 August 2021 in British Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
FHFrank G Holz
Frank G Holz
RARodrigo Abreu-Gonzalez
Rodrigo Abreu-Gonzalez
Francesco BandelloFrancesco Bandello
Francesco Bandello
RDRenaud Duval
Renaud Duval
LOLouise O'Toole
Louise O'Toole
BGBenjamin Gmeiner
Benjamin Gmeiner
Background/rationale: Artificial intelligence (AI)-based clinical decision support tools, being developed across multiple fields in medicine, need to be evaluated for their impact on the treatment and outcomes of patients as well as optimisation of the clinical workflow. TheRAZORBILLstudy will investigate the impact of advanced AI segmentation algorithms on the disease activity assessment in patients with neovascular age-related macular degeneration (nAMD) by enriching three-dimensional (3D) retinal optical coherence tomography (OCT) scans with automated fluid and layer quantification measurements.Methods: RAZORBILLis an observational, multicentre, multinational, open-label study, comprising two phases: (a) clinical data collection (phase I): an observational study design, which enforces neither strict visit schedule nor mandated treatment regimen was chosen as an appropriate design to collect data in a real-world clinical setting to enable evaluation inphase IIand (b) OCT enrichment analysis (phase II): de-identified 3D OCT scans will be evaluated for disease activity. Within this evaluation, investigators will review the scans once enriched with segmentation results (i.e., highlighted and quantified pathological fluid volumes) and once in its original (i.e., non-enriched) state. This review will be performed using an integrated crossover design, where investigators are used as their own controls allowing the analysis to account for differences in expertise and individual disease activity definitions.Conclusions: In order to apply novel AI tools to routine clinical care, their benefit as well as operational feasibility need to be carefully investigated.RAZORBILLwill inform on the value of AI-based clinical decision support tools. It will clarify if these can be implemented in clinical treatment of patients with nAMD and whether it allows for optimisation of individualised treatment in routine clinical care.